Thanks to the coordinated efforts of four major scientific organizations, this report describes the ''novel cellular therapy'' activity in Europe for the year 2009. Fifty teams from 22 countries reported data on 814 patients using a dedicated survey, which were combined to additional 328 records reported by 55 teams to the standard European Blood and Marrow Transplantation (EBMT) database. Indications were cardiovascular (37%; 64% autologous), graft-vs.-host disease (27%; 7% autologous), musculoskeletal (17%; 98% autologous), epithelial/ parenchymal (8%; 73% autologous), autoimmune (9%; 84% autologous), or neurological diseases (3%; 50% autologous). Autologous cells were used predominantly for cardiovascular (42%) and musculoskeletal (30%) disorders, whereas allogeneic cells were used mainly for graft-vs.-host disease (58%) and cardiovascular (30%) indications. Reported cell types were mesenchymal stem/stromal cells (MSC) (46%), hematopoietic stem cells (27%), chondrocytes (7%), keratinocytes (5%), dermal fibroblast (13%), and others (2%). In 59% of the grafts, cells were delivered after expansion; in 2% of the cases, cells were transduced. Cells were delivered intraorgan (46%), on a membrane or gel (29%), intravenously (16%) or using 3D scaffolds (8%). As compared to last year, the number of teams adopting the dedicated survey was 1.7-fold higher, and, with few exceptions, the collected data confirmed the captured trends. This year's edition specifically describes and discusses the use of MSC for the treatment of autoimmune diseases, due to the scientific, clinical, and economical implications of this topic.
Introduction
I n 2008, the European sections of the Tissue Engineering and Regenerative Medicine International Society (TERMIS-EU), of the International Society of Cellular Therapy (ISCT-Europe), and of the International Cartilage Repair Society (ICRS) have for the first time coordinated a joint initiative with the European Group for Blood and Marrow Transplantation (EBMT) and the European League Against Rheumatism (EULAR) to establish a comprehensive, quantitative map of patients being treated in Europe by the so-called ''novel cellular therapies,'' namely, the use of nonhematopoietic stem cells (HSC) or of HSC for nonhematological indications. The first activity report, published last year, 1 was an extension of the well-established EBMT annual report, an instrument to observe trends and to monitor changes in the use of HSC transplants for the treatment of hematologic disorders in Europe. 2, 3 The activity survey does not provide any data on specific protocols, outcome, age, or sex of patients or their pre-and post-transplant therapy. The goal of the data collection is the rapid dissemination of the status in the field of novel cellular therapies, identifying trends related to covered indications, as well as specific cell types, cell processes, and delivery modes used. Long-term analyses of the EBMT survey provided evidence that the instrument can foresee trends with high predictability and very rapidly (e.g., the increasing use of cord blood as a stem cell source, the change from bone marrow to peripheral blood or the utilization and integration of unrelated donor transplants 4, 5 ) and can thus provide a formal basis for patient counseling and healthcare planning.
In this article, we report the results of the second survey edition for the activity in 2009, with a direct comparison to the 2008 data reported last year and specifically discussing the use of mesenchymal stem/stromal cells (MSC) for the treatment of autoimmune diseases.
Patients and Methods

Data collection and validation
Participating teams were requested to report their data for 2009 by indication, cell type and source, donor type, processing method, and delivery mode. The survey followed the traditional principles of the EBMT, concentrating on numbers of patients with a first cellular therapy. For EBMT teams not using the full questionnaire, information on cellular therapies was limited to numbers of HSC for nonhematopoietic use, MSC-based therapies (later identified to be almost exclusively related to treatment of graft-vs.-host-disease), and donor type. Questionnaires were collected by paper forms or electronically. Quality control measures, for EBMT members only, included several established independent systems: confirmation 
Transplant rates
Transplant rates, defined as numbers of cellular therapies per 10 million inhabitants, were computed for each country, without adjustments for patients who crossed borders or received treatment in a foreign country. Population numbers were obtained from the U.S. census office database (www.census.gov).
Results
Number of novel cellular therapies and disease indications
According to the received reports, a total of 1142 patients were treated with novel cellular therapies, 496 (43%) with allogeneic and 646 (57%) with autologous cells (Table 1) . Main indications were cardiovascular disorders (37%; 64% autologous), graft-vs.-host disease (27%; 7% autologous), musculoskeletal disorders (17%; 98% autologous), autoimmune diseases (9%; 84% autologous), and epithelial (8%; 73% autologous) and neurological disorders (3%; 50% autologous).
From 814 patients, more detailed information was obtained concerning indications. Among the cardiovascular disorders, decubitus and leg ulcers (n = 150), myocardial ischemia (n = 111), peripheral artery disease (n = 56), and heart failure (n = 33) were the most frequently reported indications. Among the musculoskeletal disorders, cartilage repair (n = 91) and bone repair (n = 68) were the main reason for a cellular therapy. Skin reconstruction (n = 51) and cornea repair (n = 27) were the two main reported indications for epithelial/parenchymal disorders. Neurological indications were only performed for disorders not included in the form (n = 16, 8 of which for glioblastoma). Among autoimmune disorders, neurological diseases (n = 70), including multiple sclerosis, represented the predominant indication. The number of reports of patients treated for graft versus host disease (n = 19) needs to be combined with that reported in the EBMT standard form, for a total of 307 cases (Table 1) .
Cell type, source, and donor type
Of the 304 HSC treatments, 95% were autologous transplants and 80% were used to treat cardiovascular diseases ( Table 1 ). All 82 chondrocyte and 51 keratinocytes transplants were autologous and the 150 dermal (100 of which of fetal origin) fibroblasts transplants were allogeneic. Of the 520 MSC based therapies, 59% were allogeneic. The donor type was associated with the disease indication: autologous cells were used predominantly for cardiovascular (42%) and musculoskeletal (30%) disorders, whereas allogeneic cells were used mainly for graft-vs.-host disease (58%) and cardiovascular (30%) indications (Fig. 1) . In the detailed survey, MSC were obtained from bone marrow in 219 (94%) cases and mostly used to treat autoimmune (53%), musculoskeletal (31%), and cardiovascular disorders (14%). For the 264 HSC treatments, cells were derived from the bone marrow (85%), peripheral blood (8%), placenta (5%), or unspecified cell source (2%).
Cell processing and delivery mode
Of all the grafted products reported in detailed form, 59% were based on expanded cells and in 2% of the cases cells were transduced ( Table 2 ). About one half (48%) of the products was given intraorgan, 29% on a membrane or gel, 14% intravenously, and 8% using a 3D scaffold. Nonexpanded cells were used to treat 55% of cardiovascular, 38% of musculoskeletal, 38% of epithelial/parenchymal, and 31% of neurological disorders, whereas autoimmune diseases were exclusively treated with expanded cells. Cell sorting was operated for 69% of neurological, 11% of epithelial, 11% of cardiovascular, and 1% of musculoskeletal disorders. Beyond a few sporadic exceptions, reported for cardiovascular, musculoskeletal, and neurological diseases, transplanted cells were not genetically transduced.
For neurological and autoimmune applications, cells were delivered exclusively intravenous or intraorgan ( Table 3 ). The use of a membrane or a gel for cell delivery was reported mainly for cardiovascular treatments (63%), epithelial/parenchymal treatments (33%), or for cartilage repair (5%). For the group of musculoskeletal indications, all possible cell delivery modes were reported, with a predominant tendency for intraorgan (57%) and for the use a 3D scaffold (36%).
Transplant rates and active teams
Reported cellular therapies were performed in a limited number of countries and with different intensity. Figure 2 displays the cellular therapy transplant rates per 10 million inhabitants in the different European & EBMT-associated countries. High transplants rates (i.e., 40 per 10 million population) were reported in Belgium, Greece, Israel, the Netherlands, Norway, Slovenia, and Switzerland. The number of teams reporting cellular therapies was also mapped in the different European & EBMT-associated countries after normalization to the inhabitant numbers (Fig. 3) . The number of active teams per 10 million inhabitants was higher than 4 in Belgium, Greece, Israel, Lebanon, and Slovenia.
Discussion
The intersociety program of the survey on novel cellular therapies represents a unique opportunity for early access to information that integrates that available in public databases (e.g., www.clinicaltrial.gov) and that will only partially and at later times be published in the scientific literature. The 1.7fold increase in the number of participating teams within Europe and associated countries as compared to the past year demonstrates the raising interest in the program and is expected to stimulate the contribution by other groups and societies in the next years. In this regard, the list of reporting centers in the manuscript Appendix is far from being exhaustive of the effective status, but has the potential to become a key reference for the field.
As compared to the data collected for patients treated in the previous year, 1 the present report confirms the main identified trends, though with few remarkable differences, especially related to the cardiovascular diseases. For the latter indications, the number of total treated cases increased by 1.4-fold, with a 7.0-fold higher percentage for peripheral artery disease and a 1.7-fold lower percentage for myocardial ischemia. In the same category of cardiovascular disorders, the cell source shifted from entirely autologous to allogeneic in 36% of the cases, with an increase from 8% to 45% in the use of expanded cells and the introduction of a membrane or gel delivery vehicle in 37% of the treatments. The changing variety of approaches tested may be considered as a sign that several key issues still need to be settled in that field, including the optimal cell type, source and dosing, the most effective route for cell transfer, and methods for enhancing survival of the cellular graft. 6 The most uniform category within those analyzed was the one targeting autoimmune disorders. The cells used were uniquely expanded MSC, untransduced, unsorted, and delivered intravenously (19%) or intraorgan (80%). The use of MSC in modulating autoimmune diseases is an emerging area of activity in cellular therapy. 7 Based on positive animal model data and in vitro demonstration of an The positive therapeutic effect seems to be exerted via multiple paracrine factors, since transdifferentiation into healthy regenerated tissue is not considered biologically relevant. The data collected in the survey confirm that sources of MSC are autologous (requiring local GMP facilities and associated quality management systems) or allogeneic (requiring dedicated companies offering screened MSC batches derived under tightly regulated processes from bone marrow, adipose tissue, placenta, or umbilical cord). Despite the source dependent phenotypic and functional MSC variations, all have been demonstrated to exert in vitro immunomodulatory effects. More data are urgently required concerning clinical efficacy, MSC fate after transplantation, and long-term safety, especially with regard to tumor surveillance. The generation of these data will be critical to make the transition from a correctly prudent and still scattered use of MSC for autoimmune diseases to the routine clinical implementation of consolidated and standardized protocols, compliant to the regulatory framework for Advanced Therapy Medicinal Products by the European Medicines Agency (www.ema.europa.eu). The European program on novel cellular therapies is paralleled by similar initiatives in the United States, capturing the activity of 18 centers for a total of 115 treatments. 8 Despite the inherent difficulties associated with the collection and management of data across different geographical areas, for the years to come efforts should be directed at coordinated initiatives toward the establishment of a global survey and report.
